

Plumbagin Induces Cell Cycle Arrest and Autophagy and Suppresses Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR-Mediated Pathway in Human Pancreatic Cancer Cells [Retraction]

Wang F, Wang Q, Zhou ZW, et al. *Drug Des Devel Ther.* 2015;9:537–560. <https://doi.org/10.2147/DDDT.S73689>

We, the Editors and Publisher of the journal, *Drug Design, Development and Therapy*, have retracted the published article.

After publication, concerns have been raised by a third party in 2025 about the integrity of the data in Figures 6, and 10 of the article.

Further investigation conducted by the Journal and Publisher confirmed the following:

- Unusual similarities between the flow cytometry plots in Figure 6.
- Unexpected similarities between the Western blots in Figure 10 and the Western blots in the authors other article. These are representative of different samples and treatment conditions:
Wang F, Li H, Yan X, et al. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells. *Drug Des Devel Ther.* 2015;9:575–601. <https://doi.org/10.2147/DDDT.S75221>

Upon further review, the Journal and Publisher identified unexpected similarities between the Western blots in Figures 7 and 10, that are representative of different experimental conditions.

When approached for an explanation, the authors checked their data and confirmed there are fundamental errors present. Therefore, they have agreed to the retraction of this article. The authors apologise for this oversight.

As verifying the validity of published work is core to the integrity of the scholarly record, we are therefore retracting the article. The corresponding author listed in this publication has been informed.

We have been informed in our decision-making by our editorial policies and the COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as 'Retracted'.

Drug Design, Development and Therapy

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>

Dovepress
Taylor & Francis Group

<https://doi.org/10.2147/DDDT.S633642>

<https://doi.org/10.2147/DDDT.S633642>

Received: 17 June 2026

Accepted: 17 June 2026

Published: 18 June 2026

Drug Design, Development and Therapy 2026:20 633642



© 2026 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <https://www.dovepress.com/terms.php> and incorporate the Creative Commons Attribution – Non Commercial (unported, v4.0) License (<http://creativecommons.org/licenses/by-nc/4.0/>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<https://www.dovepress.com/terms.php>).